Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, P.R. China.
Med Sci Monit. 2013 Aug 7;19:648-56. doi: 10.12659/MSM.889379.
Hilar cholangiocarcinoma (HC) is a rare tumor that causes devastating disease. In the late stages, this carcinoma primarily invades the portal vein and metastasizes to the hepatic lobes; it is associated with a poor prognosis. HC is diagnosed by its clinical manifestation and results of imaging techniques such as ultrasound, computed tomography, magnetic resonance cholangiopancreatography, endoscopic retrograde cholangiography, and percutaneous transhepatic cholangiography. Preoperative hepatic bile drainage can improve symptoms associated with insufficient liver and kidney function, coagulopathy, and jaundice. Surgical margin-negative (R0) resection, including major liver resection, is the most effective and potentially curative treatment for HC. If the tumor is not resected, then liver transplantation with adjuvant management can improve survival. We conducted a systematic review of developments in imaging studies and major surgical hepatectomy for HC with positive outcomes regarding quality of life.
肝门部胆管癌（HC）是一种罕见的肿瘤，可导致严重的疾病。在晚期，这种癌主要侵犯门静脉并转移到肝叶；它与预后不良相关。HC 的诊断依据是临床表现和超声、计算机断层扫描、磁共振胰胆管成像、内镜逆行胰胆管造影和经皮经肝胆管造影等影像学技术的结果。术前肝内胆汁引流可以改善因肝功能和肾功能不足、凝血功能障碍和黄疸引起的症状。手术切缘阴性（R0）切除，包括大肝切除，是 HC 最有效的潜在治愈性治疗方法。如果肿瘤无法切除，则肝移植加辅助治疗可以改善生存。我们对 HC 的影像学研究和主要肝切除术的进展进行了系统评价，这些研究在生活质量方面取得了积极的结果。
